Cellusion obtained 1st prize of Boehringer Ingelheim Innovation Prize 2021


Tokyo, Japan (October 5, 2021)-, Cellusion Inc. (Headquarters, Tokyo; CEO: Shin Hatou, M.D., Ph.D., “Cellusion”) has been selected to 1st Prize of Boehringer Ingelheim Innovation Prize 2021. Cellusion will accelerate to deliver novel regenerative therapy for all bullous keratopathy patients.

<About Boehringer Ingelheim Innovation Prize>

For further information: please ask us through contact form in our website.

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Company : Cellusion Inc.
CEO : Shin Hatou, M.D., Ph.D.
Headquarter :1-13-7 Nihombashi-Muromachi, Chuo, Tokyo 103-0022, JAPAN
Founded : January 2015

Back to the List